Financial Snapshot For September 2004
Financial Snapshot For September 2004
In need of a boost.
Biotech: The "safe" drug bet?
Biotech: The “safe” drug bet?
“Defensive pharma stocks have struggled while biotechs have flourished. Can this continue?”
Biotech execs have a sense of humor about elusive profits
Biotech execs have a sense of humor about elusive profits
When Ernst & Young’s annual report on the biotechnology industry last year predicted that as a whole, the industry would turn profitable for the first time in 2008, some long-term industry veterans gave a knowing heard-that-one-before chuckle.
Is That a Pilot in Your Pocket?
Is That a Pilot in Your Pocket?
“Somewhere in Florida, 25,000 disembodied rat neurons are thinking about flying an F-22. “
Foresight or folly? Generics firms' foray into NCEs
Foresight or folly? Generics firms’ foray into NCEs
A number of generics firms have, over the last few years, veered off the path and started to develop innovative drugs in their own right. In a time when generics firms are showing the greatest growth in the pharmaceutical sector, what has driven them to venture into new territory?
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments